Jim Cramer on Amgen: “The Biotech Really Impressed Me With a Very Strong Pipeline”

With Amgen, I don’t cognize if you remember, astatine the JPMorgan Healthcare Conference, I heard a batch of bully things. The biotech truly impressed maine with a precise beardown pipeline. That, positive bully earnings, and possibly immoderate bully quality astir this value nonaccomplishment drug, could nonstop this Dow banal higher.

Photo by Artem Podrez connected Pexels

Amgen Inc. (NASDAQ:AMGN) delivers quality therapeutics for conditions specified arsenic cancer, cardiovascular disease, osteoporosis, and autoimmune disorders. Cramer highlighted the company’s cholesterin cause during the November 12, 2025, occurrence and said:

We had Amgen connected the amusement the different day, announcing a breakthrough successful Repatha, its each different week injection squelches cholesterin to a level wherever it helps forestall bosom attacks. Why not spell bargain that?

While we admit the imaginable of AMGN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the champion short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.